A meta-analysis of 8 trials found teriparatide increased spinal bone density by 8% and reduced vertebral fracture risk by 70% in postmenopausal women, with better results when calcium intake exceeded 1,500 mg daily.
70% fracture reductionTeriparatide reduced vertebral fracture risk by 70% compared to control in postmenopausal women with osteoporosis
What the researchers found
Teriparatide increased spine bone mineral density by 8.14% and hip BMD by 2.48% in postmenopausal women with osteoporosis. It reduced vertebral fracture risk by 70% (risk ratio 0.30) and non-vertebral fracture risk by 38% (risk ratio 0.62). Women who took more than 1,500 mg of calcium daily had significantly greater hip BMD gains (3.72% vs. 1.40%, p=0.004). Longer treatment duration did not appear to produce additional benefits.
Why it matters
Osteoporosis fractures cause enormous suffering and healthcare costs in postmenopausal women. This meta-analysis pooled data from 8 randomized controlled trials to confirm that teriparatide — a peptide fragment of parathyroid hormone — is highly effective at building bone and preventing fractures. The finding about calcium intake is practically important: adequate calcium supplementation significantly amplifies teriparatide's effect on hip bone density.
How the study worked
The researchers searched electronic databases and reference lists, identifying 8 randomized controlled trials with a combined 2,388 postmenopausal women with osteoporosis. All trials evaluated daily subcutaneous teriparatide injections. Data were pooled using a random-effects model, measuring percentage change in bone mineral density and fracture risk ratios.
Who was studied
Postmenopausal women with osteoporosis across 8 randomized controlled trials
What this study cannot tell us
Only 3 of the 8 trials reported fracture outcomes, limiting the fracture risk analysis. The meta-analysis included trials of varying duration and calcium supplementation protocols. Publication bias is possible. The analysis could not fully control for differences in study populations across trials.
How to read the evidence
This is a meta-analysis of 8 randomized controlled trials — one of the strongest forms of clinical evidence. The large combined sample and consistent results support high confidence in the findings.
When this study was published
Published in 2012. Teriparatide remains widely used, and these findings have been reinforced by subsequent research. Newer competitors like abaloparatide and romosozumab have since entered the market.
The bigger picture
Most osteoporosis drugs (like bisphosphonates) slow bone loss. Teriparatide is different — it's one of the few treatments that actually builds new bone. This meta-analysis provided strong pooled evidence supporting its use, which helped establish teriparatide as a go-to option for women at high fracture risk. The calcium finding also changed clinical practice, emphasizing that adequate calcium intake is essential to getting the full benefit.
Questions still open
- Why doesn't longer teriparatide treatment produce additional gains, and what happens to bone density after stopping?
- How does teriparatide compare to newer bone-building agents like abaloparatide and romosozumab?
- Is there a minimum calcium intake threshold below which teriparatide becomes significantly less effective?
Common questions
How much does teriparatide increase bone density?
How effective is teriparatide at preventing fractures?
Read the original research
Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
International journal of clinical practice, 66(2), 199-209
Citation
Han, S-L; Wan, S-L. (2012). Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.. International journal of clinical practice, 66(2), 199-209. https://doi.org/10.1111/j.1742-1241.2011.02837.x